Back to discover

Protein / target

Activin receptor type-2B

Encoded byACVR2BQ13705Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
1
Approved medicines
Open Targets target-level
9
Clinical trials
Small-molecule tractable
Druggability
Structure with Ligand

Protein at a glance

Biological role

Protein serine/threonine/tyrosine kinase

Strongest disease association

Heterotaxia

Via encoding gene ACVR2B · Genetic literature evidence · score 0.78

Therapeutic position

Established drug target

Antibodies

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Transmembrane serine/threonine kinase activin type-2 receptor forming an activin receptor complex with activin type-1 serine/threonine kinase receptors (ACVR1, ACVR1B or ACVR1c).

View complete UniProt function annotation

Transmembrane serine/threonine kinase activin type-2 receptor forming an activin receptor complex with activin type-1 serine/threonine kinase receptors (ACVR1, ACVR1B or ACVR1c). Transduces the activin signal from the cell surface to the cytoplasm and is thus regulating many physiological and pathological processes including neuronal differentiation and neuronal survival, hair follicle development and cycling, FSH production by the pituitary gland, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. Activin is also thought to have a paracrine or autocrine role in follicular development in the ovary. Within the receptor complex, the type-2 receptors act as a primary activin receptors (binds activin-A/INHBA, activin-B/INHBB as well as inhibin-A/INHA-INHBA). The type-1 receptors like ACVR1B act as downstream transducers of activin signals. Activin binds to type-2 receptor at the plasma membrane and activates its serine-threonine kinase. The activated receptor type-2 then phosphorylates and activates the type-1 receptor. Once activated, the type-1 receptor binds and phosphorylates the SMAD proteins SMAD2 and SMAD3, on serine residues of the C-terminal tail. Soon after their association with the activin receptor and subsequent phosphorylation, SMAD2 and SMAD3 are released into the cytoplasm where they interact with the common partner SMAD4. This SMAD complex translocates into the nucleus where it mediates activin-induced transcription. Inhibitory SMAD7, which is recruited to ACVR1B through FKBP1A, can prevent the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal. Activin signal transduction is also antagonized by the binding to the receptor of inhibin-B via the IGSF1 inhibin coreceptor

Subcellular location

Cell membrane
Domains and Gene Ontology detail (38)

Domains & features

Protein kinase

Gene Ontology

  • Cactivin receptor complex
  • Ccytoplasm
  • Cplasma membrane
  • Cprotein-containing complex
  • Creceptor complex
  • Factivin binding
  • Factivin receptor activity
  • Factivin receptor activity, type II
  • FATP binding
  • Fgrowth factor binding
  • Fkinase activator activity
  • Fmetal ion binding

512 aa · 58 kDa · 2 isoforms

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell migrationGOKinase signallingUniProt · GOTranscriptional regulationUniProt · GO
View supporting evidence

Cell migration

  • ·trophoblast cell migration

Kinase signalling

  • ·Transmembrane serine/threonine kinase activin type-2 receptor forming an activin recepto…
  • ·protein serine/threonine kinase activity
  • ·protein serine/threonine/tyrosine kinase activity
  • ·cell surface receptor protein serine/threonine kinase signaling pathway

Transcriptional regulation

  • ·Transmembrane serine/threonine kinase activin type-2 receptor forming an activin recepto…
  • ·negative regulation of transcription by RNA polymerase II
  • ·regulation of DNA-templated transcription
View underlying pathways (4)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

MSTNACVR1BINHBAGDF11TGFBR1BMP2BMP7ACVR2AACVR1CGDF2ACVR2B

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

bimagrumab
Narrow target profilePhase 3Antagonist

Activin receptor type-2B antagonist

Direct interaction with this protein · Only this protein recorded as a target

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene ACVR2B

Gene-level evidence surfaced through the gene ACVR2Bthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Heterotaxia
0.80Well supported

Genetic evidence dominant · Open Targets 0.73

Visceral heterotaxy
0.57Moderately supported

Genetic literature evidence dominant · Open Targets 0.47

Disorder of pilosebaceous unit
0.47Limited support

Genetic evidence dominant · Open Targets 0.29

Bone Diseases
0.46Limited support

Clinical evidence dominant · Open Targets 0.37

Inclusion body myositis
0.44Limited support

Clinical evidence dominant · Open Targets 0.36

View evidence synthesis (5)
HeterotaxiaWell supported
0.80
agreement 0.680.92
Genetic76%Animal model24%Genetic literaturedup

Open Targets aggregate 0.73 · 2 independent evidence families · 1 not counted as duplicate

Visceral heterotaxyModerately supported
0.57
agreement 0.430.70
Genetic literature76%Animal model24%

Open Targets aggregate 0.47 · 2 independent evidence families

Disorder of pilosebaceous unitLimited support
0.47
agreement 0.350.59
Genetic100%

Open Targets aggregate 0.29 · 1 independent evidence family

Bone DiseasesLimited support
0.46
agreement 0.300.61
Clinical99%Literature1%

Open Targets aggregate 0.37 · 2 independent evidence families

Inclusion body myositisLimited support
0.44
agreement 0.290.60
Clinical99%Literature1%

Open Targets aggregate 0.36 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Heterotaxia0.73
Visceral heterotaxy0.47
Bone Diseases0.37
Inclusion body myositis0.36
Autoimmune disorder of central nervous system0.35
Neurodegenerative Diseases0.33
Disorder of pilosebaceous unit0.29
Multiple Sclerosis0.29

Drug development

2 compounds recorded · 1 approved · 1 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 1 drug that targets this protein in Forefront's canonical graph: these count different sets and are not a subset relation.

View all recorded compounds (2)
BIMAGRUMABPhase 3
DIBOTERMIN ALFAApproval

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesEmerging

Feasibility evidence (structure with ligand and high-quality ligand) — no clinical-stage drug of this modality recorded.

AntibodiesStrong

Advanced Clinical and UniProt loc high conf support this modality.

Protein degradersEmerging

Feasibility evidence (database ubiquitination and small molecule binder) — no clinical-stage drug of this modality recorded.

Other modalitiesStrong

Approved Drug support this modality.

View underlying tractability evidence (11)
SM · Structure with LigandSM · High-Quality LigandSM · Med-Quality PocketSM · Druggable FamilyAB · Advanced ClinicalAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMPR · Database UbiquitinationPR · Small Molecule BinderOC · Approved Drug

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

9

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (5)

ClinicalTrials.gov via the drug-target graph.

What's happening now

1

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. New publication2026-03-02
    Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.

    Nature medicine · 2026 · 10 citations · Europe PMC · via bimagrumab

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.